Quantcast
Home > Quotes > PGNX
PGNX

Progenics Pharmaceuticals Inc. Common Stock (PGNX) Quote & Summary Data

$5.14
*  
0.19
3.56%
Get PGNX Alerts
*Delayed - data as of Nov. 14, 2018 14:43 ET  -  Find a broker to begin trading PGNX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    PGNX Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 5.13 / $ 5.14
1 Year Target
12
Today's High / Low
$ 5.4658 / $ 5.07
Share Volume
890,935
50 Day Avg. Daily Volume
1,550,130
Previous Close
$ 5.33
52 Week High / Low
$ 9.4172 / $ 4.675
Market Cap
434,548,522
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -0.73
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.75

Intraday Chart

Shares Traded

Share Volume:
890,935
50 Day Avg. Daily Volume:
1,550,130

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.73

Trading Range

The current last sale of $5.14 is 9.95% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 5.4658 $ 9.4172
 Low: $ 5.07 $ 4.675

Company Description (as filed with the SEC)

Progenics Pharmaceuticals, Inc. and its subsidiaries (collectively the "Company," "Progenics", "we", or "us") develop innovative medicines and other technologies to target and treat cancer. Our pipeline includes: (1) therapeutic agents designed to precisely target cancer (AZEDRA, 1095, and PSMA TTC); (2) prostate-specific membrane antigen ("PSMA") targeted imaging agents for prostate cancer (1404 and PyLTM); and (3) imaging analysis technology. Our first commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant. Progenics Pharmaceuticals, Inc. was incorporated in the State of Delaware in 1986. Pipeline Our goal is to become a preeminent, patient-centric oncology company and we intend to make a difference in how patients with prostate cancer, pheochromocytoma and paraganglioma are diagnosed and treated.  ... More ...  


Risk Grade

Where does PGNX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 5.40
Open Date:
Nov. 14, 2018
Close Price:
$ 5.33
Close Date:
Nov. 13, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x